Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Mustang Bio is expanding its pipeline beyond CAR-T cancer treatments by licensing a gene therapy from St. Jude Children's Research Hospital.
MD Anderson and Accelerator Life Science Partners unveiled Magnolia Neurosciences, to develop neuroprotective drugs with a $31 million series A.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Gemphire is halting a midphase trial testing gemcabene in pediatric nonalcoholic fatty liver disease because some patients’ disease got worse.
Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million.
A Yale University team found two potential methods for preventing fat particles from slipping into tissues.
DNAlite Therapeutics gathered $1.5 million in seed money for gene therapies that slip through the mucus typically blocking access to the GI tract.
In our EuroBiotech roundup this week, Bavarian Nordic posts RSV vaccine data, ADC starts a phase 2 trial and Silence shares a patent dispute update.
In this week's EuroBiotech Report, U.K. downplays risk of Brexit disruption, Boehringer inks gene therapy deal, Therachon raises $60 million and more.
CAR-T player Cellectis poached a Novartis exec; GSK recruited a CFO to spearhead cost-cutting; Thomas Hughes leaves Zafgen to lead Navitor; and more.
The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on the map.